Fresenius SE KGaA (XTRA:FRE) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

FRE Panoramica delle azioni

Fresenius SE & Co. KGaA, azienda del settore sanitario, fornisce prodotti e servizi per i pazienti affetti da malattie croniche.

Informazioni sull'azienda

FRE analisi fondamentale
Punteggio fiocco di neve
Valutazione	4/6
Crescita futura	3/6
Prestazioni passate	4/6
Salute finanziaria	3/6
Dividendi	0/6

Premi

Negoziato a 63.5% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 23.1% all'anno

Gli utili sono cresciuti del 29.9% nell'ultimo anno

Analisi del rischio

I pagamenti degli interessi non sono ben coperti dagli utili

Community Narratives

Narratives bring a range of perspectives from our community.

Tokyo

Community Contributor

First comes the pain, then the money.

€74.00

55.1% undervalued

24.16%

Revenue growth p.a.

about 2 months ago

Fresenius SE & Co. KGaA Concorrenti

Fresenius Medical Care

XTRA:FME

€10.2b

SYNLAB

XTRA:SYAB

€2.4b

Siemens Healthineers

XTRA:SHL

€57.4b

Labcorp Holdings

NYSE:LH

US$19.3b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Fresenius SE KGaA
Prezzi storici delle azioni
Prezzo attuale dell'azione	€33.23
Massimo di 52 settimane	€33.57
Minimo di 52 settimane	€23.93
Beta	1.06
1Variazione di 1 mese	4.30%
Variazione a 3 mesi	14.59%
Variazione di 1 anno	12.30%
3Variazione a 3 anni	-24.56%
Variazione a 5 anni	-25.17%
Variazione dall'IPO	2,843.33%

Notizie e aggiornamenti recenti

Recent updates

Investors Still Waiting For A Pull Back In Fresenius SE & Co. KGaA (ETR:FRE)

Aug 19

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Jul 15

Fresenius SE KGaA (ETR:FRE) Has Some Difficulty Using Its Capital Effectively

Jun 12

At €29.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

May 28

With Fresenius SE & Co. KGaA (ETR:FRE) It Looks Like You'll Get What You Pay For

May 02

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Mar 29

Fresenius SE KGaA (ETR:FRE) Could Be At Risk Of Shrinking As A Company

Mar 13

Why Fresenius SE & Co. KGaA (ETR:FRE) Could Be Worth Watching

Feb 06

A Look At The Fair Value Of Fresenius SE & Co. KGaA (ETR:FRE)

Jan 19

Fresenius SE & Co. KGaA's (ETR:FRE) Shares Not Telling The Full Story

Jan 03

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Nov 28

Fresenius SE & Co. KGaA (ETR:FRE) Analysts Just Trimmed Their Revenue Forecasts By 34%

Nov 10

Fresenius SE KGaA (ETR:FRE) Is Reinvesting At Lower Rates Of Return

Oct 27

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Sep 03

Some Investors May Be Worried About Fresenius SE KGaA's (ETR:FRE) Returns On Capital

Jul 25

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Jun 19

At €25.59, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Jun 01

Capital Allocation Trends At Fresenius SE KGaA (ETR:FRE) Aren't Ideal

Apr 18

Fresenius SE KGaA's (ETR:FRE) Soft Earnings Are Actually Better Than They Appear

Mar 13

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Mar 10

Are Investors Undervaluing Fresenius SE & Co. KGaA (ETR:FRE) By 38%?

Feb 23

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Feb 08

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Jan 03

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Nov 28

Should You Investigate Fresenius SE & Co. KGaA (ETR:FRE) At €21.71?

Oct 23

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Oct 01

Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?

Aug 07

Is It Time To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Jul 20

Fresenius SE KGaA (ETR:FRE) May Have Issues Allocating Its Capital

Jul 02

Fresenius SE KGaA (ETR:FRE) Is Increasing Its Dividend To €0.92

Apr 28

At €34.09, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Apr 17

Fresenius SE KGaA (ETR:FRE) Is Paying Out A Larger Dividend Than Last Year

Apr 02

Fresenius SE KGaA (ETR:FRE) Could Be Struggling To Allocate Capital

Mar 27

Fresenius SE KGaA's (ETR:FRE) Upcoming Dividend Will Be Larger Than Last Year's

Feb 24

Is Now An Opportune Moment To Examine Fresenius SE & Co. KGaA (ETR:FRE)?

Jan 13

Here's Why Fresenius SE KGaA (ETR:FRE) Has A Meaningful Debt Burden

Dec 29

Fresenius SE KGaA (ETR:FRE) Could Be Struggling To Allocate Capital

Dec 14

At €41.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Oct 15

Rendimenti per gli azionisti

	FRE	DE Healthcare	DE Mercato
7D	3.6%	1.7%	0.9%
1Y	12.3%	-1.2%	4.9%

Ritorno vs Industria: FRE ha superato il German Healthcare che ha restituito -2 % nell'ultimo anno.

Rendimento vs Mercato: FRE ha superato il mercato German che ha restituito 4.7 % nell'ultimo anno.

Volatilità dei prezzi

Is FRE's price volatile compared to industry and market?
FRE volatility
FRE Average Weekly Movement	3.1%
Healthcare Industry Average Movement	3.8%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.1%
10% least volatile stocks in DE Market	2.5%

Prezzo delle azioni stabile: FRE non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 3% ) di FRE è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1912	175,771	Michael Sen	www.fresenius.com

Fresenius SE & Co. KGaA, società operante nel settore sanitario, fornisce prodotti e servizi per i pazienti affetti da malattie croniche. Opera attraverso quattro segmenti: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios e Fresenius Vamed. Il segmento Fresenius Medical Care offre prodotti e servizi per pazienti con insufficienza renale cronica.

Fresenius SE & Co. KGaA Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Fresenius SE KGaA con la sua capitalizzazione di mercato?
FRE statistiche fondamentali
Capitalizzazione di mercato	€18.72b
Guadagni(TTM)	€721.00m
Ricavi(TTM)	€22.63b

26.0x

Rapporto P/E

0.8x

Rapporto P/S

FRE è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
FRE Conto economico (TTM)
Ricavi	€22.63b
Costo del fatturato	€17.41b
Profitto lordo	€5.23b
Altre spese	€4.51b
Guadagni	€721.00m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

Nov 06, 2024

Utile per azione (EPS)	1.28
Margine lordo	23.09%
Margine di profitto netto	3.19%
Rapporto debito/patrimonio netto	61.2%

Come si è comportato FRE nel lungo periodo?

Vedi performance storica e confronto

FRE Panoramica delle azioni

Premi

Analisi del rischio

First comes the pain, then the money.

Fresenius SE & Co. KGaA Concorrenti

XTRA:FME

€10.2b

XTRA:SYAB

€2.4b

XTRA:SHL

€57.4b

NYSE:LH

US$19.3b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Investors Still Waiting For A Pull Back In Fresenius SE & Co. KGaA (ETR:FRE)

Consensus EPS estimates fall by 34%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Fresenius SE KGaA (ETR:FRE) Has Some Difficulty Using Its Capital Effectively

At €29.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Recent updates

Investors Still Waiting For A Pull Back In Fresenius SE & Co. KGaA (ETR:FRE)

Consensus EPS estimates fall by 34%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Fresenius SE KGaA (ETR:FRE) Has Some Difficulty Using Its Capital Effectively

At €29.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

First quarter 2024 earnings released: EPS: €0.49 (vs €0.61 in 1Q 2023)

PAI Mid-Market Fund SCSp. managed by PAI Partners agreed to acquire 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

With Fresenius SE & Co. KGaA (ETR:FRE) It Looks Like You'll Get What You Pay For

Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA (XTRA:FRE).

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

New major risk - Financial position

Fresenius SE KGaA (ETR:FRE) Could Be At Risk Of Shrinking As A Company

Consensus EPS estimates fall by 11%

Why Fresenius SE & Co. KGaA (ETR:FRE) Could Be Worth Watching

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC completed the acquisition of EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE).

Consensus EPS estimates fall by 15%

Consensus EPS estimates fall by 15%

German Fresenius Reportedly Seeks to Sell Vamed Reha

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 20%

A Look At The Fair Value Of Fresenius SE & Co. KGaA (ETR:FRE)

Fresenius SE & Co. KGaA's (ETR:FRE) Shares Not Telling The Full Story

Fresenius SE & Co. KGaA to Report Fiscal Year 2023 Final Results on Mar 14, 2024

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Consensus EPS estimates increase by 57%

Fresenius SE & Co. KGaA (ETR:FRE) Analysts Just Trimmed Their Revenue Forecasts By 34%

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC agreed to acquire EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE) for €500 million.

Third quarter 2023 earnings released: €0.72 loss per share (vs €0.57 profit in 3Q 2022)

Consensus revenue estimates decrease by 46%

Fresenius SE & Co. KGaA to Report Q2, 2024 Results on Jul 31, 2024

Fresenius SE KGaA (ETR:FRE) Is Reinvesting At Lower Rates Of Return

KKR in Talks to Buy Eugin from Fresenius

Fresenius Reportedly Plans to Offload Digital Subsidiary Curalie

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Consensus EPS estimates fall by 14%

New major risk - Financial position

Second quarter 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates increase by 14%

Fresenius SE & Co. KGaA to Report Q3, 2023 Results on Nov 02, 2023

Some Investors May Be Worried About Fresenius SE KGaA's (ETR:FRE) Returns On Capital

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

At €25.59, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Fresenius Se & Co. Kgaa Proposes Dividend for 2022

Upcoming dividend of €0.92 per share at 3.3% yield

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Fresenius SE & Co. KGaA to Report Q1, 2023 Results on May 09, 2023

Capital Allocation Trends At Fresenius SE KGaA (ETR:FRE) Aren't Ideal

Consensus EPS estimates fall by 17%

Fresenius SE KGaA's (ETR:FRE) Soft Earnings Are Actually Better Than They Appear

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Full year 2022 earnings: EPS misses analyst expectations

Are Investors Undervaluing Fresenius SE & Co. KGaA (ETR:FRE) By 38%?

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Fresenius SE & Co. KGaA, Annual General Meeting, May 17, 2023

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus